ClawHub

Ipsen

v0.1.0

Ipsen is a French biopharma specializing in oncology, rare diseases, and neuroscience with a focused portfolio and global presence including a key botulinum...

⭐ 0· 22·0 current·0 all-time
by@hanxueyuan

Install

OpenClaw Prompt Flow

Install with OpenClaw

Best for remote or guided setup. Copy the exact prompt, then paste it into OpenClaw for hanxueyuan/ipsen.

Previewing Install & Setup.
Prompt PreviewInstall & Setup
Install the skill "Ipsen" (hanxueyuan/ipsen) from ClawHub.
Skill page: https://clawhub.ai/hanxueyuan/ipsen
Keep the work scoped to this skill only.
After install, inspect the skill metadata and help me finish setup.
Use only the metadata you can verify from ClawHub; do not invent missing requirements.
Ask before making any broader environment changes.

Command Line

CLI Commands

Use the direct CLI path if you want to install manually and keep every step visible.

OpenClaw CLI

Bare skill slug

openclaw skills install ipsen

ClawHub CLI

Package manager switcher

npx clawhub@latest install ipsen
Security Scan
VirusTotalVirusTotal
Benign
View report →
OpenClawOpenClaw
Benign
high confidence
✓
Purpose & Capability
Name and description match the SKILL.md content (company overview, timeline, business model). The skill requests no binaries, env vars, or config paths — which is appropriate for a read-only informational skill.
✓
Instruction Scope
SKILL.md contains only static company information and 'read_when' contexts. It does not instruct the agent to read local files, access environment variables, call external endpoints, or transmit data elsewhere.
✓
Install Mechanism
No install specification or code files are present; this minimizes surface area since nothing is written to disk or downloaded during installation.
✓
Credentials
The skill declares no required environment variables, credentials, or config paths. There is no disproportionate credential request for the stated purpose.
✓
Persistence & Privilege
always is false and the skill is user-invocable (normal defaults). It does not request persistent privileges or attempt to modify other skills or system settings.
Assessment
This skill is low-risk from a security perspective because it is instruction-only, contains static content, and requests no credentials or installs. You may still want to verify any factual claims (revenues, dates, product counts) against authoritative sources before using the information operationally. Because the skill's source/homepage is 'unknown', treat it as an unverified summary rather than an official company document.

Like a lobster shell, security has layers — review code before you run it.

latestvk971k0jkj6f78dh10pxe16znvs85n1xd
22downloads
0stars
1versions
Updated 6h ago
v0.1.0
MIT-0
@hanxueyuan
latest
Download

Ipsen

Overview

Ipsen is a French biopharmaceutical company specializing in oncology, rare diseases, and neuroscience, with a focused portfolio approach that differentiates it from big pharma diversification.

Historical Timeline

  • 1929: Founded as a small French pharmaceutical company
  • 1990s: Focuses on endocrinology and oncology specialties
  • 2010: Launches Dysport (botulinum toxin) in US market
  • 2019: Acquires Clementia Pharmaceuticals for $1.2B (fibrodysplasia drug)
  • 2022: Revenue reaches €3.1B; oncology portfolio drives growth
  • 2024: Announces major investment in radiopharmaceutical oncology

Business Model

Three therapeutic areas: Oncology (45% — Cabometyx, Onureg), Rare Disease (30% — Dysport, Somatuline), and Neuroscience (25% — Nuplazid). Revenue from prescription drug sales globally, with strong US presence through partnerships and direct sales force.

Moat Analysis

Focused portfolio in high-growth therapeutic areas (oncology, rare diseases) means deeper expertise than diversified competitors. Botulinum toxin franchise (Dysport) competes directly with Allergan's Botox. European headquarters provides advantageous pricing and regulatory environment.

Key Data

  • revenue: ~€3.3B (2023)
  • market_cap: ~€8B
  • r_and_d: ~15% of revenue
  • employees: ~6,600
  • countries: ~120

Interesting Facts

  • Ipsen's Dysport is one of only four botulinum toxin products approved by the FDA — competing directly with Botox in a $6B+ market.
  • Despite being much smaller than Big Pharma, Ipsen's oncology revenue per employee exceeds that of several major pharmaceutical companies.

Comments

Loading comments...